AZD-9833-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAZD-9833Cat. No.: HY-136255CAS No.: 2222844-89-3分式: CHFN分量: 476.51作靶点: Estrogen Receptor/ERR作通路: Others储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (209.86 mM; Need ultrasonic)

2、Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.0986 mL 10.4930 mL 20.9859 mL5 mM 0.4197 mL 2.0986 mL 4.1972 mL10 mM 0.2099 mL 1.0493 mL 2.0986 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄的储备液可以根据储存条件，适当保存；以下溶剂前的

3、百分指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 7.5 mg/mL (15.74 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 7.5 mg/mL (15.74 mM); Clear solutionBIOLOGICAL ACTIVITY1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE物活性 AZD-9833种有效的服活性雌激素受体

4、(ER) 拮抗剂。AZD-9833 可以于 ER+ HER2-乳腺癌的相关研究。IC50 & Target IC50: estrogen receptor (ER) 1体外研究 AZD-9833 is extracted from patent US20180111931A1, example 17 1.体内研究 AZD-9833 (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependentmanner in human parental MCF7 mice xeno

5、graft 1.AZD-9833 (oral administration; 0.8-40 mg/kg; 30 days)decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition atthe doses 10 mg/kg in mice 1.Animal Model: Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells infemale NSG mice

6、 1Dosage: 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kgAdministration: Oral administration; 30 days; once dailyResult: Inhibited tumor growth in a dose-dependent manner.REFERENCES1. Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-